Immunotherapy of murine hepatocellular carcinoma by α-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression

Human Gene Therapy

Volumn 19, Issue 7, 2008, Pages 753-759

  Rodríguez, María Matilde Bartolomé ^a   Ryu, Seung Min ^a   Qian, Cheng ^b   Geissler, Michael ^a   Grimm, Christian ^a   Prieto, Jesús ^b   Blum, Hubert E ^a   Mohr, Leonhard ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b University of Pamplona   (Spain)

^c Klinikum Lahr Ettenheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; MURINE ADENOVIRUS VECTOR INTERFERON INDUCIBLE PROTEIN 10; MURINE ADENOVIRUS VECTOR INTERLEUKIN 12; TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; SURVIVAL; TUMOR REGRESSION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; GENE THERAPY; IMMUNOTHERAPY; INTERLEUKIN-12; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PYRIMIDINONES; THIAZOLES; TREATMENT OUTCOME; VACCINATION; VACCINES, DNA;

ADENOVIRIDAE; ANIMALIA; MURINAE; MUS;

EID: 47549105115     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.130     Document Type: Article

References (20)

1. Butterfield, L.H. (2004). Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S232-S241.
2. Butterfield, L.H., Meng, W.S., Koh, A., Vollmer, C.M., Ribas, A., Dissette, V.B., Faull, K., Glaspy, J.A., McBride, W.H., and Economou, J.S. (2001). T cell responses to HLA-A*0201-restricted peptides derived from human α fetoprotein. J. Immunol. 166, 5300-5308.
3. Butterfield, L.H., Ribas, A., Dissette, V.B., Lee, Y., Yang, J.Q., De la Rocha, P., Duran, S.D., Hernandez, J., Seja, E., Potter, D.M., McBride, W.H., Finn, R., Glaspy, J.A., and Economou, J.S. (2006). A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res. 12, 2817-2825.
4. Drake, C.G., Jaffee, E., and Pardoll, D.M. (2006). Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81.
5. Engvall, E., Pihko, H., Jalanko, H., and Ruoslahti, E. (1977). Effect of specific immunotherapy with preimmunization against α-fetoprotein on a mouse transplantable hepatoma. J. Natl. Cancer Inst. 59, 277-280.
6. Garbi, N., Arnold, B., Gordon, S., Hammerling, G.J., and Ganss, R. (2004). CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172, 5861-5869.
7. Grimm, C.F., Ortmann, D., Mohr, L., Michalak, S., Krohne, T.U., Meckel, S., Eisele, S., Encke, J., Blum, H.E., and Geissler, M. (2000). Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119, 1104-1112.
8. Hawlisch, H., and Kohl, J. (2006). Complement and Toll-like receptors: Key regulators of adaptive immune responses. Mol. Immunol. 43, 13-21.
9. Lalor, P.F., Shields, P., Grant, A., and Adams, D.H. (2002). Recruitment of lymphocytes to the human liver. Immunol. Cell Biol. 80, 52-64.
10. Liu, M.A., Wahren, B., and Karlson Hedestam, G.B. (2006). DNA vaccines: Recent developments and future possibilities. Hum. Gene Ther. 17, 1051-1061.
11. Llovet, J.M., Burroughs, A., and Bruix, J. (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917.
12. Mizejewski, G.J., Felder, M.R., Wimer, L.T., and Ziegler, F. (1979). Characterization of murine hepatoma BW7756. I. Selected biochemical properties of liver and hepatoma. Oncology 36, 113-121.
13. Narvaiza, I., Mazzolini, G., Barajas, M., Duarte, M., Zaratiegui, M., Qian, C., Melero, I., and Prieto, J. (2000). Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164, 3112-3122.
14. Pardoll, D. (2003). Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839.
15. Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J.C., Olagüe, C., Sola, J., Sádaba, B., Lacasa, C., Melero, I., Qian, C., and Prieto, J. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22, 1389-1397.
16. Sangro, B., Melero, I., Qian, C., and Prieto, J. (2005). Gene therapy of cancer based on interleukin 12. Curr. Gene Ther. 5, 573-581.
17. Strasly, M., Cavallo, F., Geuna, M., Mitola, S., Colombo, M.P., Forni, G., and Bussolino, F. (2001). IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J. Immunol. 166, 3890-3899.
18. Sugimachi, K., Tanaka, S., Terashi, T., Taguchi, K., Rikimaru, T., and Sugimachi, K. (2002). The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression. Surgery 131(1 Suppl):S135-S141.
19. Trinchieri, G. (1998). Proinflammatory and immunoregulatory functions of interleukin-12. Int. Rev. Immunol. 16, 365-396.
20. Vollmer, C.M., Eilber, F.C., Butterfield, L.H., Ribas, A., Dissette, V.B., Koh, A., Montejo, L.D., Lee, M.C., Andrews, K.J., McBride, W.H., Glaspy, J.A., and Economou, J.S. (1999). α-Fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 59, 3064-3067.